Allspring Global Investments Holdings LLC Reduces Stake in Boston Scientific Corporation $BSX

Key Points

• Allspring Global Investments Holdings LLC has reduced its stake in Boston Scientific Corporation by 2.7%, owning approximately 1,805,476 shares valued at $189.18 million after selling 49,764 shares.
• Insider sales have been notable, including EVP Arthur C. Butcher's selling of 17,313 shares for approximately $1.81 million and EVP Joseph Michael Fitzgerald's sale of 50,000 shares for about $4.92 million.
• Analysts have raised price targets for Boston Scientific, with most recent estimates ranging from $124 to $136, maintaining a consensus rating of "Buy" for the stock.

Allspring Global Investments Holdings LLC reduced its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,805,476 shares of the medical equipment provider's stock after selling 49,764 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.12% of Boston Scientific worth $189,178,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Clarendon Private LLC boosted its stake in shares of Boston Scientific by 11.5% in the 2nd quarter. Clarendon Private LLC now owns 10,046 shares of the medical equipment provider's stock worth $1,079,000 after buying an additional 1,037 shares during the last quarter. CWM LLC boosted its stake in shares of Boston Scientific by 36.9% in the 2nd quarter. CWM LLC now owns 51,316 shares of the medical equipment provider's stock worth $5,512,000 after buying an additional 13,840 shares during the last quarter. OFI Invest Asset Management boosted its stake in shares of Boston Scientific by 34.9% in the 2nd quarter. OFI Invest Asset Management now owns 12,817 shares of the medical equipment provider's stock worth $1,377,000 after buying an additional 3,317 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Boston Scientific by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 216,910 shares of the medical equipment provider's stock worth $23,299,000 after buying an additional 37,578 shares during the last quarter. Finally, Apollon Wealth Management LLC boosted its stake in shares of Boston Scientific by 8.4% in the 2nd quarter. Apollon Wealth Management LLC now owns 24,826 shares of the medical equipment provider's stock worth $2,667,000 after buying an additional 1,929 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by company insiders.

Boston Scientific Price Performance

NYSE:BSX opened at $95.41 on Monday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The business's 50-day simple moving average is $101.98 and its two-hundred day simple moving average is $101.87. The stock has a market cap of $141.38 billion, a PE ratio of 56.79, a P/E/G ratio of 2.30 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's quarterly revenue was up 22.8% on a year-over-year basis. During the same period last year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. Robert W. Baird raised their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a report on Wednesday, October 1st. Barclays raised their target price on Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a report on Thursday, October 2nd. Wells Fargo & Company raised their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Raymond James Financial raised their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 24th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $125.00 target price on shares of Boston Scientific in a report on Monday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, Boston Scientific has a consensus rating of "Buy" and a consensus target price of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.